**Supplementary Table 1. Additional multivariable analysis of the primary composite outcome of symptomatic VTE (DVT, PE, recurrent or extending SVT\*)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|   |   |   |   |   |
|   |   | **HR** | **95% CI** | **P value** |
|  |  |  |  |  |
| After 3 months  |
|  | Cancer vs no cancer | 3.66 | 1.80–7.45 | <0.001 |
|  | Age (years) | 0.97 | 0.95–0.99 | 0.004 |
|  | Previous DVT or PE | 1.69 | 0.92–3.09 | 0.089 |
|  | Cardiovascular risk factors/diseases | 0.95 | 0.54–1.65 | 0.843 |
|  | Great saphenous vein only | 1.49 | 0.91–2.44 | 0.111 |
|  | Varicose veins  | 0.94 | 0.54–1.62 | 0.818 |
|  | Anticoagulation  | 1.15 | 0.42–3.18 | 0.788 |
|  |  |  |  |  |
| After 12 months  |
|  | Cancer vs no cancer | 2.42 | 1.31–4.50 | 0.005 |
|  | Age (years) | 0.97 | 0.96–0.99 | 0.001 |
|  | Previous DVT or PE | 1.83 | 1.16–2.89 | 0.009 |
|  | Cardiovascular risk factors/diseases | 1.11 | 0.72–1.73 | 0.629 |
|  | Great saphenous vein only | 1.20 | 0.81–1.78 | 0.370 |
|  | Varicose veins  | 1.17 | 0.74–1.86 | 0.505 |
|   | Anticoagulation  | 1.34 | 0.65–2.78 | 0.427 |
| \* Extension into the deep vein system or to < 3 cm of the saphenofemoral junction |

Abbreviations: **VTE** venous thromboembolism, **DVT** deep vein thrombosis, **PE** pulmonary embolism, **SVT** superficial vein thrombosis, **HR** hazard ratio, **CI** confidence interval

**Supplementary Table 2. Sensitivity analyses of study outcomes according to the timing of cancer diagnosis**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | **Outcomes after 3 months** |  | **Outcomes after 12 months** |
|  |  | **Patients with known****cancer at baseline** | **Patients with known cancer at baseline or cancer diagnosed within 3 months of follow-up** |  | **Patients with known****cancer at baseline** | **Patients with known cancer at baseline or cancer diagnosed within 3 months of follow-up** |
|  |  | n=70 | n=76 |  | n=70 | n=76 |
|   |   | n | % | n | % |   | n | % | n | % |
| Primary outcome |  |  |  |  |  |  |  |  |  |  |
| Symptomatic VTE (DVT, PE, recurrent or extending\* SVT) | 7 | 10.0 | 10 | 13.2 |  | 9 | 12.9 | 12 | 15.8 |
|  |  |  |  |  |  |  |  |  |  |  |
| Secondary outcomes |  |  |  |  |  |  |  |  |  |  |
|  | SVT (recurrent or extending\*) | 5 | 7.1 | 6 | 7.9 |  | 7 | 10.0 | 8 | 10.5 |
|  | PE | 0 | 0.0 | 2 | 2.6 |  | 1 | 1.4 | 3 | 4.0 |
|  | DVT | 3 | 4.3 | 3 | 4.0 |  | 3 | 4.3 | 3 | 4.0 |
|  | DVT and PE | 2 | 2.9 | 4 | 5.3 |  | 2 | 2.9 | 4 | 5.3 |
|  | Persistent SVT | 7 | 10.0 | 8 | 10.5 |  | 7 | 10.0 | 8 | 10.5 |
|  | Asymptomatic SVT\*\*  | 0 | 0.0 | 0 | 0.0 |  | 0 | 0.0 | 0 | 0.0 |
|  | Death | 0 | 0.0 | 2 | 2.6 |  | 3 | 4.3 | 5 | 6.6 |
|  | Hospitalization due to VTE | 2 | 2.9 | 3 | 4.0 |  | 2 | 2.9 | 3 | 4.0 |
|  |  |  |  |  |  |  |  |  |  |  |
| Bleeding |  | 3 | 4.3 | 3 | 4.0 |  | 3 | 4.3 | 3 | 4.0 |
| Severe bleeding |  | 1 | 1.4 | 1 | 1.3 |  | 1 | 1.4 | 1 | 1.3 |
| Clinically relevant non-major bleeding | 2 | 2.9 | 2 | 2.6 |  | 2 | 2.9 | 2 | 2.6 |

\* Extension into the deep vein system or to < 3 cm of the saphenofemoral junction

\*\* Detectable only on compression or duplex ultrasound

\*\*\* Cancer vs no cancer

Abbreviations: **VTE** venous thromboembolism, **DVT** deep vein thrombosis, **PE** pulmonary embolism, **SVT** superficial vein thrombosis